Nowadays, umbilical cord-and adipose-derived stem cells Background: (UCSCs and ASCs) are the most common sources of mesenchymal stem cells (MSCs). As part of the tumor microenvironment, MSCs are known to communicate with cancer cells via their secretomes. Increased activity of aldehyde dehydrogenase-1 (ALDH1) has been widely used as a common intrinsic stemness marker in normal and cancer stem cells. Our study aimed to elaborate on the effect of UCSC and ASC secretomes on the expression of ALDH1A3, as one of the important variants of ALDH1, TGF-β1 and TGF-β receptor type I (TβRI) in human breast cancer stem cells (BCSCs).
Introduction
Mesenchymal stem cells (MSCs) are non-hematopoietic and adherent cells characterized by high CD90, CD105 and CD73, but lack of CD14, CD34 and CD45 expression. When treated with certain differentiation-stimulating factors, these cells will differentiate into adipocytes, chondrocytes, as well as osteocytes. MSCs show clinical feasibility, as studies on multiple animal models that yielded therapeutic efficacy gave rise to a series of clinical trials in a wide range of major diseases 1 . Umbilical cord and adipose tissue are two of the most common sources of MSCs, due to the fact that they can be non-invasively obtained and have minimal risk in terms of immunological and ethical issues. Apart from sharing the common properties of MSCs, umbilical cord-derived stem cells (UCSCs) are reported to have higher proliferation capability than adipose-derived stem cells (ASCs), whereas ASCs are able to differentiate to adipose tissue better than UCSCs 2 . Very recently, we have demonstrated that both ASCs and UCSCs expressed lower ALDH1A1 and OCT-4 than breast cancer stem cells (BCSCs), indicating that both types of MSCs have lower pluripotency compared to BCSCs (Wanandi SI, Purnamawati, Tamara A, Putri KT, Simadibrata D, in press).
Nowadays, MSCs are widely used for regenerative therapies due to their multipotent differentiation capacity. On top of that, MSCs are capable to secrete various paracrine signals for tissue regeneration and revascularization, such as chemoattractive, immunomodulatory, angiogenic, anti-apoptotic, and pro-survival factors. Nevertheless, MSC secretomes have also been reported to promote cancer progression and metastasis 3 . Accumulating evidence of cell-cell and paracrine interactions between MSC and cancer cells has indicated that MSCs can either induce or inhibit tumor progression [3] [4] [5] [6] [7] [8] [9] . Secretomes contained in conditioned medium (CM) of MSCs consist of various biologically active factors that have the same effectiveness as MSCs themselves 10 . In addition, secretomes of MSCs are considered safer to use since they do not contain cellular elements, 11 making them free from possible mutations and transformation into cancer-associated fibroblast in a cancer microenvironment 12 .
Normal and cancer stem cells share similar properties, such as self-renewal capacity and differentiation potential into multiple cell types. Activity of aldehyde dehydrogenase (ALDH) superfamily have been widely used as a marker of viable normal stem cells, as well as cancer stem cells 13 . In breast cancer, the existence of ALDH+ BCSCs often correlates with poor prognosis, progression, chemoradiation resistance, and metastasis. Chemotherapy resistance is due to the role of ALDH as a detoxifying enzyme, which mediates detoxification of toxic aldehyde intermediates that are produced in certain chemotherapeutic agents-treated cancer cells, while radioresistance occurs through direct removal of oxygen radicals and indirect production of antioxidant compound nicotinamide adenine dinucleotide (phosphate) 14 . ALDH1A1 and ALDH1A3, two of ALDH1 superfamily isozymes, have been known to play important roles in the modulation of the retinoic acid signaling pathway, which can either support or suppress cancer growth [14] [15] [16] . In addition, they also serve as markers of stemness in CSCs 13, 17 . The expression of ALDH1A1 was associated with advanced, triple-negative, and poor prognosis breast cancer after neoadjuvant chemotherapy 18, 19 . ALDH1A1 expression was also found to be predictive of tumor responsiveness to cyclophosphamide treatment 20, 21 . Meanwhile, the isoform of ALDH1A3 has been suggested to promote breast cancer progression via retinoic acid signaling 22 . TGF-β family members play a major regulatory role in various biological and physiological functions 23 . TGF-β physiologically exerts anticancer activities in normal and benign cells by prohibiting cell proliferation and by creating cell microenvironments that inhibit cell motility, invasion, and metastasis. However, along with the development and progression of tumors, various mutations or deletions occur in genes that encode various TGF-β signaling components. These lead to the loss of protective and cytostatic effects of TGF-β, which in turn alters TGF-β signaling to promote cancer progression, invasion, and tumor metastasis 23, 24 . Recently, the mechanism of the TGF-β paradox may have been explained through Erk activation, which will auto-induce TGF-β in the microenvironment 25 . Autoinduction of TGF-β in benign or early stage cancer cells will create negative feedback of TGF-β signaling leading to growth arrest, whereas progression and metastasis in malignant cancer cells will be induced via a positive feedback loop 25 .
Until now, the interaction between MSC secretomes and BCSCs has not been fully understood. Our recent study has indicated that BCSCs treated with secretomes of ASCs expressed ALDH1A1 significantly higher compared to those treated with UCSCs, in accordance to OCT-4 and SOX2 expressions 26 . Those results showed that secretomes of ASCs contribute to pluripotency and viability of BCSCs more than those of UCSCs. To gain a better understanding of the effects of MSC secretomes on BCSCs, we conducted the present study on ALDH1A3 expression in association with TGF-β1 signaling pathways in BCSCs. (Table 1) .
Methods

Ethics and specimens
Statistical analysis
All relative gene expression data were analyzed using unpaired Student's t-test, SPSS 20 and presented as mean ± standard error.
Results
Morphologies of MSCs and BCSCs
BCSCs showed sphere formation within 2-3 days after plating ( Figure 1a ). UCSCs and ASCs used in this study adhered within hours after plating and displayed spindle-fibroblast-like morphology ( Indonesia. The BCSC specimen has been isolated by ALDEFLUOR™ assay for subsequent downstream assessment (Fluorescence Activated Cell Sorting in Tsukuba University, 2015).
Cell cultures
MSCs were grown in Minimum Essential Medium Alpha (α-MEM) supplemented with 10% FBS, while BCSCs were grown in non-serum DMEM/F12 medium. Both cell cultures were supplemented with 1% penicillin-streptomycin and 1% amphotericin. Cells were incubated under standard conditions (5% CO 2 and 37°C). The media were replaced every 3 days and cells were subcultured when confluence was obtained.
Preparation of MSC-conditioned medium (MSC-CM)
Early-passage human MSCs (P3-P5) were grown to 70-80% confluence in α-MEM medium with 10% FBS. Culture medium was removed and the cells were washed three times by PBS 1x to remove any residual serum. The cells were then grown in non-serum α-MEM medium under standard conditions for 24 hours. MSC-CM was centrifuged at 200xg for 10 min to remove cell debris and filtered using 0.22 μm filters. Subsequently, CM was stored at -20°C and used within 3 days. To prepare the CM for each experiment, CM was diluted with DMEM/F12 to obtain a 50% (v/v) concentration.
Incubation of BCSCs (ALDH+) with MSC-CM and viability assay BCSCs (ALDH+) were harvested and counted using an automatic cell counter (Luna ® ). About 5 x 10 5 cells with more than 90% viability were grown in non-serum DMEM/F12 medium. After 24 hours, the BCSC medium was replaced with 50% (v/v) MSCs-CM. After 72 hours of incubation, cells were harvested and counted using Tryphan blue exclusion dye assay. Cells that were grown in 50% (v/v) non-serum α-MEM medium were used as a control. The experiment was performed in triplicate. Human BCSCs were treated with 50% (v/v) UCSC-CM and ASC-CM, respectively. As a control, BCSCs were treated in 50% (v/v) non-serum α-MEM medium. After 72-hour incubation, total RNA was isolated and quantitative reverse transcriptase PCR was performed to determine ALDH1A3 mRNA expression levels in human BCSCs.The Cq obtained was normalized to 18S rRNA and control cells. Data is presented as mean ± SE. Significance differences are considered at *p<0.05; **p<0.01 (Student's t-test). BCSCs, breast cancer stem cells; UCSCs, umbilical cord-derived stem cells; ASCs, adipose-derived stem cells; CM, conditioned medium.
RNA isolation and qRT-PCR assay
effect of ASC-was significantly lower than that of UCSC-CM (p=0.024) These results indicate that ALDH1A3 was distinctly expressed in BCSCs treated with UCSC-and ASC-CM. 
Expression of TGF-β1 and TβRI genes in BCSCs treated with CM of UCSCs and ASCs (Figure 3)
In attempt to analyze the effect of MSC-CM on TGF-β signaling, we determined the relative mRNA expressions of TGF-β1 and its receptor, TβRI. UCSC-CM significantly increases the relative expression of TGF-β1 (1.72 times, p=0.003) and TβRI (1.54 times, p=0.000). In contrast to this data, ASCs-CM significantly decreases the expression of TGF-β1 (0.64, p=0.003) and TβRI (0.76, p=0.014) in BCSCs compared with controls. Additionally, UCSC-and ASC-CM showed differential effects on either TGF-β1 (p=0.000) or TβRI (p=0.000) expression of BCSCs, suggesting that UCSC and ASC secretomes may be different in content and levels of growth factors, thereby influencing differential regulation of TGF-β1 and TβRI expressions. Relative expression of TGF-β1 (A) and TβRI (B) mRNA in BCSCs. Human BCSCs were treated with 50% (v/v) UCSC-CM and ASC-CM, respectively. As a control, BCSCs were treated in 50% (v/v) non-serum α-MEM medium. After 72-hour incubation, total RNA was isolated and quantitative reverse transcriptase PCR was performed to determine TGF-β1 and TβRI mRNA expression levels in human BCSCs. The Cq obtained was normalized to 18S rRNA and control cells. Data is presented as mean ± SE). Significance differences are considered at *p<0.05; **p<0.01; ***p<0.001 (Student's t-test). BCSCs, breast cancer stem cells; UCSCs, umbilical cord-derived stem cells; ASCs, adipose-derived stem cells; CM, conditioned medium. TbRI Cq was used to calculate TbRI mRNA expression levels using Livak formula as demonstrated in Figure 3B 
Discussion
Recently, the utilization of secretomes contained within MSC-CM has begun to be performed on various rejuvenation therapies. However, the possible consequences that may arise due to the interaction between biologically active factors (secretomes) and cancer cells has not yet been elucidated. As with MSCs, their secretomes have also been reported to either suppress or promote growth and development of cancer 3 . These contradictory effects may be due to different composition of secretomes, with one of the causes being the fact that they are obtained from different MSC sources 4, 28 .
In this study, we found that secretomes within UCSC-CM have a higher ability to promote ALDH1A3 gene expression in BCSCs, indicating the higher paracrine signaling activity of UCSC secretomes when compared to those of ASCs (Figure 2 ). This result is in contrast with the effect of MSC secretomes on ALDH1A1 expression of BCSCs demonstrated in our previous study, which revealed that ALDH1A1 mRNA expression was significantly reduced by UCSC-CM and increased by ASC-CM 26 . In that study, we also found that ALDH1A1 expression is in line with the expression of OCT-4 and SOX2. Therefore, we suggest that unlike ALDH1A1, ALDH1A3 does not prominently contribute to the pluripotency of BCSCs. This has been verified by in silico analysis that showed that there is no direct interaction between ALDH1A3 and pluripotency markers, OCT4, SOX2, NANOG, and KLF4 (in press; Wanandi SI, Purnamawati, Tamara A, Putri KT, Simadibrata D). That study has also indicated that ALDH1A1 expression levels in MSCs were more similar to OCT4 rather than to ALDH1A3 levels, suggesting the role of ALDH1A1 on pluripotency.
In the present study, we highlighted that the effects of UCSC and ASC secretomes on ALDH1A3 were consistent with the expressions of TGF-β1 and its receptor, TβRI, in BCSCs (Figure 3) . In spite of that, the effects of UCSC on ALDH1A3, TGF-β1, and TβRI expressions were opposite to those of ASC secretomes, in which UCSC up-regulated, while ASC secretomes down-regulated those gene expressions. Previous studies have reported that different MSC sources have different growth factor contents and levels 4, 28 . Very recently, we have also demonstrated that UCSCs and ASCs expressed different levels of either ALDH1A1 or ALDH1A3 (in press; <Wanandi SI, Purnamawati, Tamara A, Putri KT, Simadibrata D>). These two isozymes of ALDH1 have newly been confirmed to have differential functional roles in facilitating aggressiveness of human breast cancer cells 29 . ALDH1A1 suppresses proliferation, metastatic properties and therapy resistance of breast cancer cells, whereas ALDH1A3 has predominant effect on ALDH activity. These results supported our previous study that presented the increase of viability and pluripotency in ASC secretomes-treated BCSCs in line with the increase of ALDH1A1
26
. Moreover, the current study also underlines the effect of UCSC and ASC secretomes on TGF-β1 autocrine signaling in BCSCs, as revealed by TGF-β1 and its receptor, TβRI expressions ( Figures 3A and B) . We suggest that secretomes of UCSCs and ASCs presumably contained growth factors including TGF-β1 that could auto-induce TGF-β1 signaling in BCSCs. Due to TGF-β1 paradox, tumor proliferation could be stimulated or inhibited either via differential ERK depending on relative level of TGF-β1 present in tumor microenvironment 25 . A plausible explanation of TGF-β1 autocrine signaling induction in our BCSCs is as a cellular homeostasis against reduced cell viability and pluripotency due to enhanced ALDH1A3 and diminished ALDH1A1 expression after supplementation with UCSC secretomes 26, 28 .
In conclusion, the differential effects of UCSC and ASC secretomes on ALDH1A3 expression in human BCSCs may be related to autocrine TGF-β1 signaling, as opposed to ALDH1A1 which regulates BCSC viability and pluripotency. In depth studies are further required to elaborate signaling factors within UCSC and ASC secretomes that specifically regulate ALDH1A1 and ALDH1A3 expressions in relation to TGF-β1 autocrine signaling and its impact on the aggressiveness of BCSCs. 
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These results speak to the difficulty of modeling the interactions of stromal cells and cancer cells. Using freshly isolated human breast cancer cells, flow-sorted on the basis light scatter and expression of CD90, we found that co-injection of adipose stromal cells in a xenograft model increased tumorgenicity of active, but not resting tumor cells. In vitro, coculture of unpassaged breast cancer cells with adipose stromal cells greatly increased their proliferation . The take-home is that the state of the cancer cells matters as much as the the signals provided by the stromal cells and microenvironment. To complicate matters further, stromal cells themselves can be polarized into pro-and anti-inflammatory states resulting in different secretomes.
At a minimum, the authors should provide detailed information about the preparation of their "breast cancer stem cells", as these are not standard reagents.
Additionally, UC-and adipose-conditioned media have not been characterized for cytokine/chemokine content. This is relatively simple to do, as multiplexed kits are commercially available and would significantly contribute to a more mechanistic understanding of the data.
A minor consideration: wording such as "nowadays" and "on top of that" are rather colloquial for a scientific publication. 
